Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
TRANSLATIONAL LUNG CANCER RESEARCH(2019)
摘要
There were many clinical studies on lung cancer in 2018. In particular, significant progress has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have shown good results. For patients with specific gene mutations, the new generation inhibitors also showed good results in clinical trials. In this review, we summarize the clinical trials in lung cancer in 2018 and describe the progress and prospects for lung cancer therapies.
更多查看译文
关键词
Non-small cell lung cancer (NSCLC),small cell lung cancer (SCLC),immunotherapy,targeted therapy,clinical trails
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络